Whalesbook
Toh bhai, Biocon ne Canada ke market mein ekdum entry maardi hai apne do naye denosumab biosimilars, Bosaya aur Vevzuo ke saath. Health Canada ne April 3, 2026 ko inko green signal de diya hai. Isse Biocon ab Canada mein osteoporosis aur cancer ki wajah se hone wali bone complications ke liye affordable treatments provide kar payegi. Yeh unki global biosimilar strategy ka ek bohot bada step hai.
Health Canada ki yeh 'Notice of Compliance' Bosaya (jo Prolia ka biosimilar hai) aur Vevzuo (Xgeva ka biosimilar) ke liye kaafi important hai. Company ke CEO Shreehas Tambe ne kaha ki yeh patients ko high-quality biosimilars tak access pahunchane ka ek crucial step hai. Waise Biocon ke shares filhaal ₹358 se ₹362 ke aas paas traded ho rahe hain, daily volume lagbhag 2 million shares ka hai. Company ki market cap around ₹58,000 crore hai.
Lekin yahan ek twist hai! Canada ka denosumab biosimilar market pehle se hi kaafi bhara hua hai. Apotex, Sandoz, Celltrion jaise bade players yahan pehle se maujood hain, aur aur bhi aane wale hain. Iska matlab Biocon ko market share paane ke liye aur competition face karni padegi, aur smart pricing strategy apnani padegi.
Analysts ka is situation par mix view hai. ICICIdirect ne is stock par HOLD rating di hai aur target price ₹230 set kiya hai, jismein woh price erosion aur badhti hui competition ko risk maan rahe hain. Lekin doosri taraf, HSBC ne Buy rating di hai aur target ₹425 rakha hai. Woh market mein entry ki difficulties toh maante hain, par company ke overall outlook par positive hain.
Biocon ka main goal toh yahi hai ki woh duniya bhar mein affordable aur high-quality biologic therapies pahunchaye. Canada ka yeh approval unki scientific aur regulatory capabilities ko bhi show karta hai. HSBC aur Stockopedia jaise analysts isko future growth ka bada driver dekh rahe hain, jiska consensus target price around ₹425 hai. Bas company ko competitive pressures aur pricing challenges ko carefully manage karna hoga.